| Acquired by | Sanofi Aventis |
| Price | $770M |
| Date | 7/09 |
| Terms | Stock |
| Website | shanthabiotech.com |
| Category | BioTech |
| Employees | |
| Founded | 1993 |
| Description | Vaccine Maker |
Shantha was created in 1993 by Dr. Varaprasad Reddy and is based in Hyderabad, India. Shantha develops, manufactures and markets several vaccines. It operates at international standards in a state-of-the-art facility.
Shantha works with supranational organizations like UNICEF and PAHO to supply major international markets including Asia-Pacific, Africa and Latin America. In 1997, Shantha launched SHANVAC-Bâ„¢, the first recombinant Hepatitis B vaccine produced in India. SHANVAC-Bâ„¢, SHANTETRAâ„¢ (combination vaccine of Diphteria, Pertussis, Tetanus and Hepatitis B), SHAN5â„¢ (combination vaccine of Diphteria, Pertussis, Tetanus, Haemophilus influenza B and Hepatitis B) and SHANTTâ„¢ (Tetanus toxoid vaccine) are prequalified by the World Health Organization for supplying to United Nation agencies globally. Shantha also has an important portfolio of vaccines in development.
